NCT02999646View on ClinicalTrials.gov

Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

January 25, 2023

Study Completion Date

June 29, 2023

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
OTHER

MVX-ONCO-1

Autologous cells: 1 vial containing 4x10\^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10\^5 MVX-1 cells

Trial Locations (4)

1211

HUG Hôpitaux Universitaires Genève, Geneva

8091

Universitätsspital Zürich, Zurich

CH-1011

Centre Hospitalier Universitaire Vaudois CHUV, Lausanne

CH-9007

Kantonsspital St. Gallen, Sankt Gallen

Sponsors

Lead Sponsor

Maxivax SA
All Listed Sponsors
collaborator

European Commission

OTHER

lead

Maxivax SA

INDUSTRY